Search hospitals > Colorado > Denver
National Jewish Health
Claim this profileDenver, Colorado 80206
Global Leader in Fibrosing Colonopathy
Global Leader in Cystic Fibrosis
Conducts research for Asthma
Conducts research for Pulmonary Disease
Conducts research for Fibrosing Alveolitis
474 reported clinical trials
26 medical researchers
Summary
National Jewish Health is a medical facility located in Denver, Colorado. This center is recognized for care of Fibrosing Colonopathy, Cystic Fibrosis, Asthma, Pulmonary Disease, Fibrosing Alveolitis and other specialties. National Jewish Health is involved with conducting 474 clinical trials across 505 conditions. There are 26 research doctors associated with this hospital, such as Nicholas DiBella, Benjamin J. George, Marwan Massouh, and Karng S. Log.Area of expertise
1Fibrosing Colonopathy
Global LeaderCFTR
CFTR positive
F508del
2Cystic Fibrosis
Global LeaderCFTR
CFTR positive
F508del
Top PIs
Nicholas DiBellaRocky Mountain Cancer Centers-Boulder6 years of reported clinical research
Expert in Parotid Gland Cancer
Expert in Breast Cancer
103 reported clinical trials
193 drugs studied
Benjamin J. GeorgeSCL Health Good Samaritan Medical Center Cancer Centers of Colorado6 years of reported clinical research
Studies Lymphoma
Studies Esophageal Cancer
12 reported clinical trials
48 drugs studied
Marwan MassouhSaint James Community Hospital and Cancer Treatment Center7 years of reported clinical research
Studies Parotid Gland Cancer
Studies Lung Cancer
11 reported clinical trials
35 drugs studied
Karng S. LogLutheran Hospital - Cancer Centers of Colorado2 years of reported clinical research
Studies Small Cell Lung Cancer
Studies Colon Cancer
10 reported clinical trials
32 drugs studied
Clinical Trials running at National Jewish Health
Breast Cancer
Fibrosing Colonopathy
Cystic Fibrosis
Lung Cancer
Idiopathic Pulmonary Fibrosis
Breast cancer
Fibrosing Alveolitis
Asthma
Insomnia
Non-Small Cell Lung Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at National Jewish Health?
Where is National Jewish Health located?
Who should I call to ask about financial aid or insurance network?
What insurance does National Jewish Health accept?
What awards or recognition has National Jewish Health received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.